Lenalidomid Grindeks (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the complex’s target proteins, leading to the degradation of transcription factors that promote tumor growth, while also exerting anti‑angiogenic and immune‑enhancing effects.

The dose of Lenalidomid Grindeks is individualized by the prescribing clinician based on the specific indication, patient characteristics, and treatment goals. Only a qualified healthcare professional should determine the appropriate regimen.

Lenalidomid Grindeks is classified as teratogenic and should not be used during pregnancy. Women of child‑bearing potential must use effective contraception. Safety during breastfeeding has not been established, so the drug is generally avoided while nursing.

To request Lenalidomid Grindeks, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomid Grindeks belongs to the immunomodulatory imide drug class, offering a distinct mechanism from proteasome inhibitors or monoclonal antibodies. It is often used in combination regimens and provides benefits such as oral administration and a different side‑effect profile, making it a valuable option in multi‑drug treatment strategies.

Store Lenalidomid Grindeks tablets at temperatures below 25 °C in their original packaging. Protect the tablets from moisture and direct sunlight to maintain stability and potency throughout the shelf life.

Lenalidomid Grindeks is taken orally as a tablet, usually with or without food as directed by the prescriber. Patients should follow the dosing schedule provided by their healthcare professional and not alter the regimen without medical advice.

The most serious risks include severe neutropenia, venous thromboembolism, secondary primary malignancies, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for signs of infection, clotting events, or unusual skin changes.

Lenalidomid Grindeks should not be used by individuals who are pregnant, have uncontrolled infections, or have a known hypersensitivity to lenalidomide or any component of the tablet. It is also contraindicated in patients with severe renal or hepatic impairment unless specifically approved by a specialist.